In a recent study published in Nature Immunology, a team of researchers from the United States used non-human primate models to compare the protection conferred by an intramuscular booster dose of the bivalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine with that provided by a booster dose of a mucosal bivalent adenoviral vector vaccine delivered through an aerosol device or intranasal route.
Background
The rapidly developed COVID-19 vaccines were successful in limiting the severity and transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, and the intramuscular booster doses continue to confer protection against high levels of morbidity and hospitalization.
However, studies have shown that the efficacy of intramuscularly administered bivalent mRNA vaccines vane after approximately four months, while breakthrough SARS-CoV-2 infections continue to occur.
Factors such as age, immunocompromised conditions, and post-acute sequelae could influence innate immunity levels and vaccine response, increasing the probability of breakthrough infections.
Vaccines that can prevent breakthrough infections would be effective in lowering the transmission levels and preventing the emergence of novel SARS-CoV-2 variants.
A mucosal vaccine, administered intranasally, could limit the transmission of SARS-CoV-2 by boosting the plasma cells and memory B cells in the lymphoid tissue associated with the mucosa and increasing the immune responses at the site of the infection.
About the study
In the present study, the researchers used Macaca mulatta or rhesus macaques to investigate the protective immune responses elicited by a mucosal bivalent adenoviral vector vaccine containing stabilized spike protein from the ancestral Wuhan strain and the Omicron BA.5 variant of SARS-CoV-2.
They compared these immune responses against those elicited by an intramuscular booster dose of a bivalent mRNA vaccine encoding the spike proteins of the same two variants.
Although the inflammation and pathology due to severe disease in humans are not completely recapitulated in non-human primate models, studies have shown that the virus readouts and immune responses observed in non-human primate models can be used to predict the clinical outcomes for Omicron infections in humans.
The adenoviral vector vaccine used in the study was the ChAd-SARS-CoV-2-S vaccine, which is currently being administered in the form of nasal drops in India under the name iNCOVACC. Viral vector vaccines using adenovirus, Newcastle disease virus, or parainfluenza virus can elicit immune responses at the site of the infection, making these vaccines an ideal candidate for a mucosal, intranasally administered booster dose.
The rhesus macaques in the study were primed with two intramuscular doses of an mRNA vaccine encoding the spike protein from the ancestral Wuhan strain.
Seven months after they were primed, one group of macaques was administered with the bivalent ChAd-SARS-CoV-2-S vaccine through an aerosol device, and the vaccine was delivered to the lower and upper airways.
A second group was administered the vaccine intranasally in the form of a mist using a clinical sprayer. In contrast, a comparison group was intramuscularly administered a booster dose of the bivalent mRNA vaccine.
The protection conferred by the mucosal adenoviral vector vaccine administered through aerosol and intranasal routes and the intramuscular booster dose of the bivalent mRNA vaccine were compared by challenging the animals with the XBB.1.16 strain of the virus four and a half months after the booster doses were administered.
Results
The study found that the viral replication in the lungs and the nose of the animals that were administered the mucosal adenoviral vector vaccine against SARS-CoV-2 was minimal for the animals in both the aerosol and intranasal administration groups.
In contrast, the animals that were intramuscularly administered the booster dose of the bivalent mRNA vaccine showed lower levels of viral replication only in the lower airways.
The mucosal vaccine also resulted in durable immunoglobulin (Ig) A and IgG responses in the airways and activated B cells specific for the spike protein in the lungs, which was not observed in the case of the intramuscular bivalent mRNA vaccine booster dose.
The study found that the aerosolized delivery of the mucosal vaccine elicited broad mucosal immunity in multiple respiratory compartments, which could rapidly suppress the replication of SARS-CoV-2.
In comparison, the intranasally administered booster dose of the same vaccine could only boost the IgA titers in the airway, which could prevent the local replication of the virus but could not inhibit viral replication in the lungs as effectively as the aerosolized booster dose or elicit memory B cells specific to the spike protein.
Conclusions
Overall, the findings showed that a booster dose of mucosal adenoviral vector vaccine against SARS-CoV-2, administered as an aerosol, was most effective in controlling viral replication in the lungs and the nose.
The IgA titers in the airways were indicative of the protection in the upper respiratory compartments. In contrast, memory B cell and T cell responses, as well as IgA and IgG titers, correlated with the protection conferred in the lower airways.
- Gagne, M., Flynn, B.J., Andrew, S.F., Marquez, J., Flebbe, D.R., Mychalowych, A., Lamb, E., DavisGardner, M.E., Burnett, M.R., Serebryannyy, Leonid A, Lin, B.C., Ziff, Z.E., Maule, E., Carroll, R., Naisan, M., Jethmalani, Y., Pessaint, L., Todd, J.M., DoriaRose, N.A. & Case, J.B. (2024). Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates. Nature Immunology. doi:10.1038/s41590024019515. https://www.nature.com/articles/s41590-024-01951-5
News
Scientists Discover a Hidden “Immune Organ” Inside the Skull
Researchers discovered lymph node-like immune hubs inside skull bone marrow that appear to act as rapid-response centers for the brain. For decades, the brain was thought to operate largely apart from the immune system. [...]
Engineered tRNAs and lipid nanoparticles target nonsense mutation cystic fibrosis
Researchers have developed a potential new approach for treating a form of cystic fibrosis caused by so-called nonsense mutations, combining chemically modified transfer RNAs with lipid nanoparticles designed to deliver the therapy directly to [...]
New pancreatic cancer drug carries a $39,800 monthly list price
A groundbreaking treatment for one of the most common forms of pancreatic cancer has been approved in pill form by the FDA. Revolution Medicines’ oral tablet daraxonrasib, branded as Rasonque, reduced the risk of [...]
Researchers Have Discovered a New Way To Reduce Chronic Nerve Pain
A cancer-linked protein called BRAF may help drive chronic nerve pain, and existing cancer drugs targeting it reduced pain sensitivity in preclinical models. Chronic nerve pain can persist long after an injury and often [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Quantum-Enabled Regenerative Health: Reimagining Wellness, Precision Health and Longevity Medicine
Introduction Healthcare is approaching a frontier where the quantum portfolio could influence not only how disease is diagnosed and treated, but how health itself is measured, modeled, predicted and preserved. Quantum computing, quantum simulation, [...]
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
